{"filing":{"accession_number":"0001636422-26-000091","cik":"0001636422","ticker":"HCAT","company_name":"Health Catalyst, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-07-31","primary_document":"hcat-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636422/000163642226000091/hcat-20260731.htm"},"events":[{"id":25920,"run_id":23535,"accession_number":"0001636422-26-000091","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Health Catalyst completed the divestiture of VitalWare, LLC to Med-Metrix, LLC on July 31, 2026, for a base purchase price of $147 million. The company used the proceeds to prepay and terminate its credit facility, representing a significant strategic transaction affecting the company's asset base and financial position.","company_name":"Health Catalyst, Inc.","ticker":"HCAT","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26859,"accession_number":"0001636422-26-000091","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"Item 1.02 discloses termination of a credit facility through full repayment of $122.8M principal, $37.1M delayed draw facility, and associated fees totaling approximately $163M. While the Item title is \"Termination,\" the substance is debt repayment and facility termination, not issuance. However, the exhibit earnings release emphasizes this as a positive balance-sheet event (\"fully repaid our credit facility debt, which significantly improves our balance sheet\"), suggesting the material event is the elimination of debt obligations rather than creation of new ones. This is most accurately classified as debt elimination/repayment, which does not fit neatly into the taxonomy—it is the inverse of debt_issuance. The closest fit is financial_other, as it represents a material change in capital structure and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26860,"accession_number":"0001636422-26-000091","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Health Catalyst completed the divestiture of VitalWare, LLC to Med-Metrix, LLC on July 31, 2026, for a base purchase price of $147 million. This is a material disposition of assets under Item 2.01, representing a significant strategic transaction that affects the company's asset base and financial position. The company used proceeds to prepay and terminate its credit facility, demonstrating material financial impact.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25921,"run_id":23535,"accession_number":"0001636422-26-000091","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Health Catalyst issued a Q2 2026 earnings release on August 6, 2026 disclosing financial results for the quarter ended June 30, 2026, including revenue of $70.5M, net loss of $40.5M, and Adjusted EBITDA of $9.9M, along with forward guidance for Q3 and full-year 2026.","company_name":"Health Catalyst, Inc.","ticker":"HCAT","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26861,"accession_number":"0001636422-26-000091","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Health Catalyst issued a press release on August 6, 2026 disclosing financial results for the quarter ended June 30, 2026, including GAAP and non-GAAP metrics (revenue of $70.5M, net loss of $40.5M, Adjusted EBITDA of $9.9M), forward guidance for Q3 and full-year 2026, and a condensed consolidated balance sheet and statements of operations. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26862,"accession_number":"0001636422-26-000091","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces completion of the Vitalware divestiture via press release (Exhibit 99.2), but the substantive content furnished is Health Catalyst's Q2 2026 earnings release (Exhibit 99.1), which reports quarterly financial results including revenue of $70.5M, net loss of $(40.5)M, and adjusted EBITDA of $9.9M, along with forward guidance for Q3 and full-year 2026. The earnings release is the primary material disclosure here.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26859,"accession_number":"0001636422-26-000091","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"Item 1.02 discloses termination of a credit facility through full repayment of $122.8M principal, $37.1M delayed draw facility, and associated fees totaling approximately $163M. While the Item title is \"Termination,\" the substance is debt repayment and facility termination, not issuance. However, the exhibit earnings release emphasizes this as a positive balance-sheet event (\"fully repaid our credit facility debt, which significantly improves our balance sheet\"), suggesting the material event is the elimination of debt obligations rather than creation of new ones. This is most accurately classified as debt elimination/repayment, which does not fit neatly into the taxonomy—it is the inverse of debt_issuance. The closest fit is financial_other, as it represents a material change in capital structure and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"Health Catalyst, Inc.","ticker":"HCAT","filing_date":"2026-08-06"},{"id":26860,"accession_number":"0001636422-26-000091","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Health Catalyst completed the divestiture of VitalWare, LLC to Med-Metrix, LLC on July 31, 2026, for a base purchase price of $147 million. This is a material disposition of assets under Item 2.01, representing a significant strategic transaction that affects the company's asset base and financial position. The company used proceeds to prepay and terminate its credit facility, demonstrating material financial impact.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"Health Catalyst, Inc.","ticker":"HCAT","filing_date":"2026-08-06"},{"id":26861,"accession_number":"0001636422-26-000091","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Health Catalyst issued a press release on August 6, 2026 disclosing financial results for the quarter ended June 30, 2026, including GAAP and non-GAAP metrics (revenue of $70.5M, net loss of $40.5M, Adjusted EBITDA of $9.9M), forward guidance for Q3 and full-year 2026, and a condensed consolidated balance sheet and statements of operations. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"Health Catalyst, Inc.","ticker":"HCAT","filing_date":"2026-08-06"},{"id":26862,"accession_number":"0001636422-26-000091","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces completion of the Vitalware divestiture via press release (Exhibit 99.2), but the substantive content furnished is Health Catalyst's Q2 2026 earnings release (Exhibit 99.1), which reports quarterly financial results including revenue of $70.5M, net loss of $(40.5)M, and adjusted EBITDA of $9.9M, along with forward guidance for Q3 and full-year 2026. The earnings release is the primary material disclosure here.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:00.408628+00:00","company_name":"Health Catalyst, Inc.","ticker":"HCAT","filing_date":"2026-08-06"}]}